Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B
Journal of Medical Virology · 2025-02 · 97 (2)
DOI: 10.1002/jmv.70187 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medical Virology, online erschienen am 27.01.2025. Verfasst von Log Young Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Big DATA Strategy, National Health Insurance Service, Wonju, Bucheon, South Korea. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Guanine, Tenofovir, Antiviral Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: This work was supported by the Soonchunhyang University Research Fund., Soonchunhyang University.
Abstract (Originalsprache)
While entecavir (ETV) and tenofovir disoproxil fumarate (TDF) effectively manage chronic hepatitis B, their long‐term effects on lipid metabolism and cardiovascular outcomes remain unclear. This study compares the impact of ETV, TDF, and treatment‐naïve (control group) on hyperlipidemia and major adverse cardiac events (MACE) in people living with chronic hepatitis B (PLWHB). We used claim data from the South Korean National Health Insurance Service. Propensity score matching was used to account for confounding factors. The 5‐year cumulative incidence of dyslipidemia was 7.10% for TDF, 12.17% for ETV, and 18.55% for the control group, with incidence rates per 1000 person‐years of 14.5, 25.5, and 38.9, respectively. TDF showed a significantly lower risk of dyslipidemia compared to ETV (IRR: 0.56, p < 0.001) and the control group, which was confirmed in Cox regression analysis (HR: 0.392 vs. control, p < 0.001). For MACE, the 5‐year cumulative incidence was 9.11% for TDF, 10.98% for ETV, and 12.32% for the control group, with incidence rates per 1000 person‐years of 18.4, 22.5, and 24.8, respectively. TDF demonstrated a reduced risk compared to ETV (IRR: 0.817, p < 0.001), which was similarly supported by Cox regression analysis (HR: 0.728 vs. control, p < 0.001). In conclusion, TDF not only reduces the risk of hyperlipidemia but is also associated with a reduced risk of MACE compared to ETV or treatment‐naive group in PLWHB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Big DATA Strategy, National Health Insurance Service, Wonju, Bucheon, South Korea.
- Department of Internal Medicine, Soonchunhyang University School of Medicine, Asan, Bucheon, South Korea.
- Division of Gastroenterology and Hepatology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, South Korea.
ORCID-Profile: Log Young Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young-Seok Kim
Förderung
- This work was supported by the Soonchunhyang University Research Fund.
- Soonchunhyang University
Zitieren
APA
Kim, L. Y., Kim, J. Y., Yoo, J. J., Kim, S. G., & Kim, Y. S. (2025). Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B. Journal of Medical Virology, 97(2). https://doi.org/10.1002/jmv.70187
Vancouver
Kim LY, Kim JY, Yoo JJ, Kim SG, Kim YS. Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B. Journal of Medical Virology. 2025;97(2). doi:10.1002/jmv.70187
BibTeX
@article{Kim2025,
author = {Kim, Log Young and Kim, Jae Young and Yoo, Jeong-Ju and Kim, Sang Gyune and Kim, Young-Seok},
title = {Tenofovir Disoproxil Fumarate Versus Entecavir: Effects on Lipid Profiles and Cardiovascular Outcomes in People Living With Chronic Hepatitis B},
journal = {Journal of Medical Virology},
year = {2025},
volume = {97},
number = {2},
doi = {10.1002/jmv.70187}
}
EUVIMED